ReviewOman medical journal2021
Group A
Review in Oman medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Effects of an Herbal Formulation Ethanolic Extract onPathogens (Basel, Switzerland) · 2026Article
- Anti-Streptococcal Activity of β-Thujaplicin and Its Effect on Natural Low-Level Resistance ofPathogens (Basel, Switzerland) · 2026Article
- Article
- The burden of group AiScience · 2025Review
- Streptococcus pyogenes carriage rate, associated factors and antimicrobial susceptibility profiles among urban and rural schoolchildren at Gondar city, Northwest Ethiopia.Scientific reports · 2025Article
- Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy AgainstAntibiotics (Basel, Switzerland) · 2024Review
- Inhibition ofmSphere · 2024Article
- Fabrication of a Microfluidic Test Device with a 3D Printer and Its Combination with the Loop Mediated Isothermal Amplification Method to DetectMicromachines · 2024Article
- OvercomingActa pharmaceutica Sinica. B · 2022Review
- Discovery of a novel antibacterial protein CB6-C to target methicillin-resistant Staphylococcus aureus.Microbial cell factories · 2022Article
- Prevalence and predicting factors of Group A beta-hemolyticAnnals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives
methodsWe identified all published studies up to 20 March 2019 related to
resultsOur analysis indicated the following prevalence pattern for
conclusionsOur findings suggest penicillin (in non-allergic children) and macrolides, lincosamides, and narrow-spectrum cephalosporins (in penicillin-allergic children) as the treatments of choice in Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.